Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 12/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946662 | 0.87 | CFTR (0.38) | KIF18A | |
| SCHEMBL9944806 | 0.85 | ALDH1A1 (0.41) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL9944991 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1POLBTHRBRECQL | |
| SCHEMBL9944989 | 0.84 | ALDH1A1 (0.44) | ALDH1A1GAA | |
| SCHEMBL9944767 | 0.80 | GAA (0.45) | KDM4EALDH1A1TDP1GAA | |
| SCHEMBL9945033 | 0.80 | GAA (0.45) | KDM4EALDH1A1TDP1GAA | |
| SCHEMBL9944950 | 0.79 | RAB9A (0.40) | KIF18AKDM4EALDH1A1POLBGAA | |
| SCHEMBL9946615 | 0.76 | PTGES (0.43) | — | |
| SCHEMBL9944847 | 0.76 | ALDH1A1 (0.43) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL9944821 | 0.76 | ALOX15 (0.39) | KIF18AKDM4EALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | KIF18A 4848/4885KDM4E 3442/4885ALDH1A1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.